Ignite Creation Date:
2024-05-06 @ 1:28 PM
Last Modification Date:
2024-10-26 @ 1:15 PM
Study NCT ID:
NCT04038489
Status:
WITHDRAWN
Last Update Posted:
2021-11-22
First Post:
2019-07-10
Brief Title:
COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER HER2- Stage I-III Breast Cancer
Sponsor:
University of Virginia
Organization:
University of Virginia
Study Overview
Official Title:
COX Inhibition and Biomarkers of Response During Neoadjuvant Chemoendocrine Therapy for Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Stage I-III Breast Cancer
Status:
WITHDRAWN
Status Verified Date:
2021-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Lack of accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Breast 51
Brief Summary:
This study is designed to assess the safety and clinical activity of tamoxifen and the COX inhibitor aspirin given in combination with standard AC-T chemotherapy doxorubicin cyclophosphamide and paclitaxel for the treatment of high-risk estrogen receptor ER human epidermal growth factor receptor 2 HER2- breast cancer If successful the study could improve long-term outcomes for a subpopulation of women with aggressive stage I-III ERHER2- breast cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None